Status: Not yet recruiting
Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor
At a median follow-up of 33 months, the combination of anastrozole and NOLVADEX (tamoxifen citrate) did not demonstrate any efficacy benefit when compared to NOLVADEX (tamoxifen citrate) therapy given alone in all patients as well as in the hormone receptor positive subpopulation. This treatment arm was discontinued from the trial. This study is now a combination therapy whereas the median duration of adjuvant treatment for safety evaluation is 59.8 months and 59.6 months for patients receiving anastrozole 1 mg and NOLVADEX (tamoxifen citrate) 20 mg, respectively.
Participants needed: 100
Trial details
Age: 44-59Biological sex: AllType: ObservationalSponsor: DR. DIANE CHISESI NFS. MD. PHD.Updated: Dec 4, 2023Locations: 1Duration: 90 Days
Eligibility criteria
The Median Duration of Adjuvant Treatment for 59.8 Months and 59.6 Months for Pa... [+28]
At a median follow-up of 33 months, the combination of anastrozole and NOLVADEX...